Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. Mehta RS, et al. Among authors: marcoux c. Transplant Cell Ther. 2023 Mar;29(3):189-198. doi: 10.1016/j.jtct.2022.11.027. Epub 2022 Dec 5. Transplant Cell Ther. 2023. PMID: 36470579 Free PMC article.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Br J Haematol. 2023 Aug;202(4):866-873. doi: 10.1111/bjh.18944. Epub 2023 Jun 27. Br J Haematol. 2023. PMID: 37376789 Free PMC article.
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Maze D, et al. Bone Marrow Transplant. 2024 Feb;59(2):196-202. doi: 10.1038/s41409-023-02146-6. Epub 2023 Nov 8. Bone Marrow Transplant. 2024. PMID: 37938736 Free PMC article.
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.
Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei P. Marcoux C, et al. Blood Adv. 2024 Mar 12;8(5):1128-1136. doi: 10.1182/bloodadvances.2023011233. Blood Adv. 2024. PMID: 38266155 Free PMC article.
Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Maze D, et al. Bone Marrow Transplant. 2024 Feb;59(2):295. doi: 10.1038/s41409-023-02194-y. Bone Marrow Transplant. 2024. PMID: 38279008 Free PMC article. No abstract available.
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades.
Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Transplant Cell Ther. 2024 Aug;30(8):772.e1-772.e11. doi: 10.1016/j.jtct.2024.06.001. Epub 2024 Jun 7. Transplant Cell Ther. 2024. PMID: 38852784
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p.
Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Marcoux C, et al. Transplant Cell Ther. 2024 Oct 22:S2666-6367(24)00728-0. doi: 10.1016/j.jtct.2024.10.011. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39448031
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Blood Cancer J. 2024 Oct 31;14(1):189. doi: 10.1038/s41408-024-01165-w. Blood Cancer J. 2024. PMID: 39482325 Free PMC article.
14 results